At the gene level, the relationship was significant for CH defined by JAK2 (n = 139, β = −1.03, P < 1 × 10–300) and TET2 (n = 788, β = −1.94, P = 4.50 × 10–4) variants but not DNMT3A or ASXL1. Again, for all tests there was no evidence for heterogeneity between the discovery and validation cohorts (P > 0.05, Cochran’s Q test). The gene discussed is TET2; the disease is cyclic hematopoiesis.